205 related articles for article (PubMed ID: 24406045)
1. Wnt antagonist, secreted frizzled-related protein 4 (sFRP4), increases chemotherapeutic response of glioma stem-like cells.
Warrier S; Balu SK; Kumar AP; Millward M; Dharmarajan A
Oncol Res; 2013; 21(2):93-102. PubMed ID: 24406045
[TBL] [Abstract][Full Text] [Related]
2. Secreted Frizzled-related protein 4 (sFRP4) chemo-sensitizes cancer stem cells derived from human breast, prostate, and ovary tumor cell lines.
Deshmukh A; Kumar S; Arfuso F; Newsholme P; Dharmarajan A
Sci Rep; 2017 May; 7(1):2256. PubMed ID: 28536422
[TBL] [Abstract][Full Text] [Related]
3. Cancer stem-like cells from head and neck cancers are chemosensitized by the Wnt antagonist, sFRP4, by inducing apoptosis, decreasing stemness, drug resistance and epithelial to mesenchymal transition.
Warrier S; Bhuvanalakshmi G; Arfuso F; Rajan G; Millward M; Dharmarajan A
Cancer Gene Ther; 2014 Sep; 21(9):381-8. PubMed ID: 25104726
[TBL] [Abstract][Full Text] [Related]
4. Netrin-like domain of sFRP4, a Wnt antagonist inhibits stemness, metastatic and invasive properties by specifically blocking MMP-2 in cancer stem cells from human glioma cell line U87MG.
Yasmin IA; Mohana Sundaram S; Banerjee A; Varier L; Dharmarajan A; Warrier S
Exp Cell Res; 2021 Dec; 409(2):112912. PubMed ID: 34762897
[TBL] [Abstract][Full Text] [Related]
5. Secreted frizzled-related protein 4 inhibits glioma stem-like cells by reversing epithelial to mesenchymal transition, inducing apoptosis and decreasing cancer stem cell properties.
Bhuvanalakshmi G; Arfuso F; Millward M; Dharmarajan A; Warrier S
PLoS One; 2015; 10(6):e0127517. PubMed ID: 26030909
[TBL] [Abstract][Full Text] [Related]
6. Wnt inhibition is dysregulated in gliomas and its re-establishment inhibits proliferation and tumor sphere formation.
Kierulf-Vieira KS; Sandberg CJ; Grieg Z; Günther CC; Langmoen IA; Vik-Mo EO
Exp Cell Res; 2016 Jan; 340(1):53-61. PubMed ID: 26712519
[TBL] [Abstract][Full Text] [Related]
7. Wnt3a mediated activation of Wnt/β-catenin signaling promotes tumor progression in glioblastoma.
Kaur N; Chettiar S; Rathod S; Rath P; Muzumdar D; Shaikh ML; Shiras A
Mol Cell Neurosci; 2013 May; 54():44-57. PubMed ID: 23337036
[TBL] [Abstract][Full Text] [Related]
8. The Combined Treatment with Chemotherapeutic Agents and the Dualsteric Muscarinic Agonist Iper-8-Naphthalimide Affects Drug Resistance in Glioblastoma Stem Cells.
Guerriero C; Matera C; Del Bufalo D; De Amici M; Conti L; Dallanoce C; Tata AM
Cells; 2021 Jul; 10(8):. PubMed ID: 34440646
[TBL] [Abstract][Full Text] [Related]
9. Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine for the treatment of malignant glioma.
Wang Y; Huang N; Li H; Liu S; Chen X; Yu S; Wu N; Bian XW; Shen HY; Li C; Xiao L
Oncotarget; 2017 Jun; 8(23):37511-37524. PubMed ID: 28415586
[TBL] [Abstract][Full Text] [Related]
10. Frizzled 4 regulates stemness and invasiveness of migrating glioma cells established by serial intracranial transplantation.
Jin X; Jeon HY; Joo KM; Kim JK; Jin J; Kim SH; Kang BG; Beck S; Lee SJ; Kim JK; Park AK; Park WY; Choi YJ; Nam DH; Kim H
Cancer Res; 2011 Apr; 71(8):3066-75. PubMed ID: 21363911
[TBL] [Abstract][Full Text] [Related]
11. Fenretinide (4-HPR) Targets Caspase-9, ERK 1/2 and the Wnt3a/β-Catenin Pathway in Medulloblastoma Cells and Medulloblastoma Cell Spheroids.
Bassani B; Bartolini D; Pagani A; Principi E; Zollo M; Noonan DM; Albini A; Bruno A
PLoS One; 2016; 11(7):e0154111. PubMed ID: 27367907
[TBL] [Abstract][Full Text] [Related]
12. Proteins of the Wnt signaling pathway as targets for the regulation of CD133+ cancer stem cells in glioblastoma.
Shevchenko V; Arnotskaya N; Korneyko M; Zaytsev S; Khotimchenko Y; Sharma H; Bryukhovetskiy I
Oncol Rep; 2019 May; 41(5):3080-3088. PubMed ID: 30864699
[TBL] [Abstract][Full Text] [Related]
13. Secreted frizzled-related protein 4 regulates two Wnt7a signaling pathways and inhibits proliferation in endometrial cancer cells.
Carmon KS; Loose DS
Mol Cancer Res; 2008 Jun; 6(6):1017-28. PubMed ID: 18567805
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy resistance of glioblastoma stem cells.
Eramo A; Ricci-Vitiani L; Zeuner A; Pallini R; Lotti F; Sette G; Pilozzi E; Larocca LM; Peschle C; De Maria R
Cell Death Differ; 2006 Jul; 13(7):1238-41. PubMed ID: 16456578
[No Abstract] [Full Text] [Related]
15. Correlation between low-level expression of the tumor suppressor gene TAp73 and the chemoresistance of human glioma stem cells.
Hu X; Wu N; Xia P; Yu S; Sun F; Chen J
Cancer Chemother Pharmacol; 2012 May; 69(5):1205-12. PubMed ID: 22258403
[TBL] [Abstract][Full Text] [Related]
16. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
[TBL] [Abstract][Full Text] [Related]
17. The Wnt/β-catenin pathway regulates self-renewal of cancer stem-like cells in human gastric cancer.
Cai C; Zhu X
Mol Med Rep; 2012 May; 5(5):1191-6. PubMed ID: 22367735
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of breast cancer stem-like cells by a triterpenoid, ursolic acid, via activation of Wnt antagonist, sFRP4 and suppression of miRNA-499a-5p.
Mandal S; Gamit N; Varier L; Dharmarajan A; Warrier S
Life Sci; 2021 Jan; 265():118854. PubMed ID: 33278391
[TBL] [Abstract][Full Text] [Related]
19. Krüppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells.
Tung B; Ma D; Wang S; Oyinlade O; Laterra J; Ying M; Lv SQ; Wei S; Xia S
BMC Cancer; 2018 Oct; 18(1):1025. PubMed ID: 30348136
[TBL] [Abstract][Full Text] [Related]
20. Stemness, Pluripotentiality, and Wnt Antagonism: sFRP4, a Wnt antagonist Mediates Pluripotency and Stemness in Glioblastoma.
Bhuvanalakshmi G; Gamit N; Patil M; Arfuso F; Sethi G; Dharmarajan A; Kumar AP; Warrier S
Cancers (Basel); 2018 Dec; 11(1):. PubMed ID: 30591679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
